At a glance
ClinicalIndex Comparison RecordN/ACompleted· 45 enrolled
Drug / intervention
Optivedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation de la gêne Oculaire après Injections intravitréennes
In Brief
A clinical study evaluating Optive for Macular Degeneration and 3 related conditions. Completed, enrolled 45 participants across 1 site.
Detailed Summary
In this study, ocular discomfort following intravitreal injection in naïve patients will be studied, as well as the efficacy of wetting agent (Optive eyewash) to prevent ocular discomfort.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMacular Degeneration, Diabetic Retinopathy, Retinal Artery Occlusion, Myopia, Degenerative
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartApr 2016
First PostedJun 2016
Primary CompletionJan 2017
Study CompletionJul 2017
TodayJul 2026
First PostedJun 21, 2016
Enrollment StartApr 1, 2016
Primary CompletionJan 1, 2017
Study CompletionJul 1, 2017
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.0 years ago
Interventions
Optivedrug
Optive eye drops will be prescribed to each included patients after their second intravitreal injection; patients will received 1 drop in the affected eye 2 times a day during 3 days